{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:07:11Z","timestamp":1785535631638,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T00:00:00Z","timestamp":1521158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40257-018-0352-y","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T08:10:32Z","timestamp":1521187832000},"page":"275-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%\/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison"],"prefix":"10.1007","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct02735421","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Brigitte","family":"Dr\u00e9no","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Gagn\u00e9-Henley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Barankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Kerrouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,16]]},"reference":[{"issue":"4","key":"352_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2230.1994.tb01200.x","volume":"19","author":"AM Layton","year":"1994","unstructured":"Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol. 1994;19(4):303\u20138.","journal-title":"Clin Exp Dermatol."},{"issue":"Suppl 1","key":"352_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000246015","volume":"195","author":"AM Layton","year":"1997","unstructured":"Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology. 1997;195(Suppl 1):15\u201321 (discussion 38\u201340).","journal-title":"Dermatology."},{"issue":"2","key":"352_CR3","first-page":"97","volume":"16","author":"J Tan","year":"2017","unstructured":"Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the Unites States. J Drugs Dermatol. 2017;16(2):97\u2013102.","journal-title":"J Drugs Dermatol."},{"issue":"6","key":"352_CR4","first-page":"566","volume":"16","author":"J Tan","year":"2017","unstructured":"Tan J, Bourd\u00e8s V, Bissonnette R, et al. Prospective study of pathogenesis of atrophic acne scars and role of macular erythema. J Drugs Dermatol. 2017;16(6):566\u201372.","journal-title":"J Drugs Dermatol."},{"issue":"2S1","key":"352_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","volume":"78","author":"DM Thiboutot","year":"2018","unstructured":"Thiboutot DM, Dr\u00e9no B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in Acne. J Am Acad Dermatol. 2018;78(2S1):S1\u201323.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"352_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s13555-017-0185-2","volume":"7","author":"J Leyden","year":"2017","unstructured":"Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293\u2013304.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"352_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1365-2133.2001.04276.x","volume":"145","author":"A Thielitz","year":"2001","unstructured":"Thielitz A, Helmdach M, Ropke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol. 2001;145:19\u201327.","journal-title":"Br J Dermatol."},{"key":"352_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaad.2004.10.879","volume":"54","author":"D Thiboutot","year":"2006","unstructured":"Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006;54:242\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"352_CR9","first-page":"145","volume":"76","author":"DM Pariser","year":"2005","unstructured":"Pariser DM, Thiboutot DM, Clark SD, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis. 2005;76:145\u201351.","journal-title":"Cutis"},{"key":"352_CR10","first-page":"s24","volume":"7","author":"JS Weiss","year":"2008","unstructured":"Weiss JS, Thiboutot DM, Hwa J, et al. Long-term safety and efficacy study of adapalene gel 0.3%. J Drugs Dermatol. 2008;7:s24\u20138.","journal-title":"J Drugs Dermatol"},{"key":"352_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1468-3083.2007.02190.x","volume":"21","author":"A Thielitz","year":"2007","unstructured":"Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol. 2007;21:747\u201353.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"9","key":"352_CR12","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/jdv.13675","volume":"30","author":"HP Gollnick","year":"2016","unstructured":"Gollnick HP, Bettoli V, Lambert J, et al. A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol. 2016;30(9):1480\u201390.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"11","key":"352_CR13","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1099\/ijsem.0.001367","volume":"66","author":"CF Scholz","year":"2016","unstructured":"Scholz CF, Kilian M. The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and Pseudopropionibacterium gen. nov. Int J Syst Evol Microbiol. 2016;66(11):4422\u201332.","journal-title":"Int J Syst Evol Microbiol."},{"key":"352_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1067\/mjd.2003.618","volume":"49","author":"H Gollnick","year":"2003","unstructured":"Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49:S1\u201337.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"352_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40257-016-0178-4","volume":"17","author":"L Stein Gold","year":"2016","unstructured":"Stein Gold L, Weiss J, Rueda MJ, et al. Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3%\/benzoyl peroxide 2.5% gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17(3):293\u2013303.","journal-title":"Am J Clin Dermatol."},{"issue":"12","key":"352_CR16","first-page":"1427","volume":"14","author":"J Weiss","year":"2015","unstructured":"Weiss J, Stein Gold L, Leoni M, et al. Customized single-agent therapy management of severe inflammatory acne: a randomized, double-blind, parallel-group, controlled study of a new treatment\u2014adapalene 0.3%-benzoyl peroxide 2.5% gel. J Drugs Dermatol. 2015;14(12):1427\u201335.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"352_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13555-016-0159-9","volume":"7","author":"H Osman-Ponchet","year":"2017","unstructured":"Osman-Ponchet H, Sevin K, Gaborit A, et al. Fixed-combination gels of adapalene and benzoyl peroxide provide optimal percutaneous absorption compared to monad formulations of these compounds: results from two in vitro studies. Dermatol Ther (Heidelb). 2017;7(1):123\u201331.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10","key":"352_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/j.1365-4632.2011.05029.x","volume":"50","author":"GJ Goodman","year":"2011","unstructured":"Goodman GJ. Treatment of acne scarring. Int J Dermatol. 2011;50(10):1179\u201394 (Review).","journal-title":"Int J Dermatol."},{"key":"352_CR19","first-page":"CD011946","volume":"4","author":"R Abdel Hay","year":"2016","unstructured":"Abdel Hay R, Shalaby K, Zaher H, et al. Interventions for acne scars. Cochrane Database Syst Rev. 2016;4:CD011946.","journal-title":"Cochrane Database Syst Rev."},{"key":"352_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0231-8","author":"M Loss","year":"2018","unstructured":"Loss M, Leung S, Chien A et al. Adapalene 0.3% gel shows efficacy for the treatment of atrophic acne scars. Dermatol Ther (Heidelb). 2018. https:\/\/doi.org\/10.1007\/s13555-018-0231-8.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"4","key":"352_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jdv.14026","volume":"31","author":"B Dreno","year":"2017","unstructured":"Dreno B, Tan J, Rivier M, et al. Adapalene 0.1%\/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial. J Eur Acad Dermatol Venereol. 2017;31(4):737\u201342.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"352_CR22","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0002-9440(10)62479-0","volume":"166","author":"S Kang","year":"2005","unstructured":"Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166(6):1691\u20139.","journal-title":"Am J Pathol."},{"issue":"5","key":"352_CR23","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/sj.jid.5700213","volume":"126","author":"NR Trivedi","year":"2006","unstructured":"Trivedi NR, Gilliland KL, Zhao W, et al. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling. J Investig Dermatol. 2006;126(5):1071\u20139.","journal-title":"J Investig Dermatol."},{"issue":"Suppl 2","key":"352_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1034\/j.1600-0625.12.s2.6.x","volume":"12","author":"G Uchida","year":"2003","unstructured":"Uchida G, Yoshimura K, Kitano Y, et al. Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid derived fibroblasts. J Exp Dermatol. 2003;12(Suppl 2):35\u201342.","journal-title":"J Exp Dermatol"},{"issue":"8","key":"352_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1056\/NEJM199308193290803","volume":"329","author":"CE Griffiths","year":"1993","unstructured":"Griffiths CE, Russman AN, Majmudar G, et al. Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med. 1993;329(8):530\u20135.","journal-title":"N Engl J Med."},{"issue":"2 Pt 3","key":"352_CR26","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/S0190-9622(98)70446-3","volume":"39","author":"S Kang","year":"1998","unstructured":"Kang S, Voorhees JJ. Photoaging therapy with topical tretinoin: an evidence-based analysis. J Am Acad Dermatol. 1998;39(2 Pt 3):S55\u201361 (Review).","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"352_CR27","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/jdv.14379","volume":"31","author":"A Bouloc","year":"2017","unstructured":"Bouloc A, Roo E, Imko-Walczuk B, et al. A skincare combined with combination of adapalene and benzoyl peroxide provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne. J Eur Acad Dermatol Venereol. 2017;31(10):1727\u201331.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"4","key":"352_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s13555-017-0203-4","volume":"7","author":"T Myhill","year":"2017","unstructured":"Myhill T, Coulson W, Nixon P, et al. Use of supplementary patient education material increases treatment adherence and satisfaction among acne patients receiving adapalene 0.1%\/benzoyl peroxide 2.5% gel in primary care clinics: a multicenter, randomized, controlled clinical study. Dermatol Ther (Heidelb). 2017;7(4):515\u201324.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"352_CR29","doi-asserted-by":"crossref","unstructured":"Tan J, Bissonnette R, Gratton D et al. The safety and efficacy of four different fixed combination regimens of adapalene 0.1%\/benzoyl peroxide 2.5% gel in the treatment of acne vulgaris: results from a randomized controlled study. Eur J Dermatol. 2018 (in press).","DOI":"10.1684\/ejd.2018.3367"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-018-0352-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:38:07Z","timestamp":1628617087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-018-0352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,16]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0352-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,16]]},"assertion":[{"value":"16 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Galderma R&D\/Nestle Skin Health. Open access was funded by Galderma R&D\/Nestle Skin Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The investigators (JT, RB, AGH, BB, CL, BD) received financial support for conducting the study. Dr. B. Dr\u00e9no has been an investigator and\/or consultant for Bioderma, Galderma, Pierre Fabre, and La Roche Posay. Dr. R. Bissonnette has been an investigator, consultant, advisory board member, and speaker for BioPharmX, Cipher, Dermira, Galderma, GSK-Stiefel, Valeant, and Xenon and is a shareholder of Innovaderm Research. Dr. A. Gagn\u00e9-Henley has been an investigator, consultant, advisory board member, and\/or speaker for Abbvie, Celgene, Dignity, Galderma, Janssen, Leo pharma, Novartis, Sanofi, Valeant, and Xenon. Dr. B. Barankin has been a consultant and speaker for Galderma. Dr. C. Lynde has been a consultant, advisory board member, and speaker for Bayer, Galderma, GSK, and Valeant. Dr. J. Tan has been an investigator, consultant, advisory board member, and speaker, and has provided expert testimony, for Galderma. Mr N. Kerrouche is an employee of Galderma R&D.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and in compliance with the International Conference on Harmonization-Good Clinical Practice and local regulatory requirements. The study was reviewed and approved by the appropriate Independent Ethics Committees, and written informed consent was obtained from all subjects prior to study initiation. Additional informed consent was obtained from all individual participants whose photographs are included in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}